## Drug resistance interpretation: PR

HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: None
PI Accessory Mutations: None
PR Other Mutations: I13V • I15IV • E35D • N37S • R41K • R57RK • L63LP • I64V

| Protease Inhibitors | |
|---|---|
| **atazanavir/r (ATV/r)** | Susceptible |
| **darunavir/r (DRV/r)** | Susceptible |
| **fosamprenavir/r (FPV/r)** | Susceptible |
| **indinavir/r (IDV/r)** | Susceptible |
| **lopinavir/r (LPV/r)** | Susceptible |
| **nelfinavir (NFV)** | Susceptible |
| **saquinavir/r (SQV/r)** | Susceptible |
| **tipranavir/r (TPV/r)** | Susceptible |

## Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

*No drug resistance mutations were found for PI.*

## Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations: None
NNRTI Mutations: K103N
RT Other Mutations: V35T • E40ED • K49R • V60I • V90VI • D177EG • V179VI • G196E • T200I • Q207GR • R211K • V245K • D250E • K530R • A534S • V548I • A554N

| Nucleoside Reverse Transcriptase Inhibitors | |
|---|---|
| **abacavir (ABC)** | Susceptible |
| **zidovudine (AZT)** | Susceptible |
| **stavudine (D4T)** | Susceptible |
| **didanosine (DDI)** | Susceptible |
| **emtricitabine (FTC)** | Susceptible |
| **lamivudine (3TC)** | Susceptible |
| **tenofovir (TDF)** | Susceptible |

| Non-nucleoside Reverse Transcriptase Inhibitors | |
|---|---|
| **doravirine (DOR)** | Susceptible |
| **efavirenz (EFV)** | High-Level Resistance |
| **etravirine (ETR)** | Susceptible |
| **nevirapine (NVP)** | High-Level Resistance |
| **rilpivirine (RPV)** | Susceptible |

**RT comments**

**NNRTI**

- **K103N** is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.

**Other**

- **V90I** is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It is associated with minimal, if any, detectable reduction in NNRTI susceptibility.
- **V179I** is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

## Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

*No drug resistance mutations were found for NRTI.*

*Drug resistance mutation scores of NNRTI:* Download CSV

| Rule | DOR | EFV | ETR | NVP | RPV |
|---|---|---|---|---|---|
| K103N | 0 | 60 | 0 | 60 | 0 |

## Drug resistance interpretation: IN

HIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations: None
INSTI Accessory Mutations: None
IN Other Mutations: E10D • K14KR • K34KR • M50L • I72V • L101LI • T112V • I113V • T124A • T125A • V201I • L234I • A265V

| Integrase Strand Transfer Inhibitors | |
|---|---|
| **bictegravir (BIC)** | Susceptible |
| **cabotegravir (CAB)** | Susceptible |
| **dolutegravir (DTG)** | Susceptible |
| **elvitegravir (EVG)** | Susceptible |
| **raltegravir (RAL)** | Susceptible |

## Mutation scoring: IN

HIVDB 9.5.1 (2023-11-05)

*No drug resistance mutations were found for INSTI.*